Apyx Medical Corp (APYX) — SEC Filings
Apyx Medical Corp (APYX) — 38 SEC filings. Latest: 8-K (May 11, 2026). Includes 16 8-K, 9 SC 13G/A, 6 10-Q.
View Apyx Medical Corp on SEC EDGAR
Overview
Apyx Medical Corp (APYX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 19, 2025: On November 17, 2025, APYX Medical Corporation entered into a material definitive agreement. The company, formerly known as BOVIE MEDICAL Corp and AN CON GENETICS INC, is incorporated in Delaware and headquartered in Clearwater, Florida. This filing is a current report under the Securities Exchange
Sentiment Summary
Across 38 filings, the sentiment breakdown is: 1 bearish, 35 neutral, 2 mixed. The dominant filing sentiment for Apyx Medical Corp is neutral.
Filing Type Overview
Apyx Medical Corp (APYX) has filed 16 8-K, 6 10-Q, 2 DEF 14A, 1 10-K, 1 SC 13G, 9 SC 13G/A, 1 SC 13D/A, 2 SC 13D with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (38)
Risk Profile
Risk Assessment: Of APYX's 24 recent filings, 1 were flagged as high-risk, 11 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $33.680M |
| Net Income | -$9.865M |
| EPS | N/A |
| Debt-to-Equity | 8.44 |
| Cash Position | $25.135M |
| Operating Margin | -19.2% |
| Total Assets | $57.365M |
| Total Debt | $34.607M |
Key Executives
- Stavros G. Vizirgianakis
- Amy E. Culbert, Esq.
Industry Context
The medical aesthetics industry is characterized by innovation and regulatory oversight. Companies like APYX Medical compete by developing and obtaining FDA clearance for new devices. Market success hinges on product efficacy, physician adoption, and patient demand, often influenced by economic conditions and marketing efforts.
Top Tags
corporate-governance (5) · medical-devices (5) · amendment (5) · financials (4) · institutional-ownership (4) · Medical Devices (3) · SEC Filing (3) · 10-Q (3) · 8-K (3) · corporate-filing (2)
Executive Compensation
From the most recent DEF 14A filing (Jun 25, 2025):
- N/A — President and Chief Executive Officer: $0
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Commission File Number | 001-31885 | Identifies the company's filing with the SEC |
| I.R.S. Employer Identification No. | 11-2644611 | Company's tax identification number |
| Q3 2025 Sales | $12.877M | Increased from $11.487 million in Q3 2024 |
| Q3 2025 Net Loss | $1.955M | Improved from $4.724 million net loss in Q3 2024 |
| Nine Months 2025 Net Loss | $9.865M | Improved from $18.900 million net loss in nine months 2024 |
| Nine Months 2025 Sales | $33.680M | Slightly decreased from $33.880 million in nine months 2024 |
| Annualized Cost Savings | $4.3M | Expected from November 2024 workforce reduction |
| Maximum Operating Expense Target | $40.0M | For full year 2025, per Perceptive Credit Agreement |
| Surgical Aesthetics Revenue Target | $37.0M | For full year 2025, per Perceptive Credit Agreement |
| Long-term Debt, Net | $34.607M | Outstanding with Perceptive Credit Holdings IV, LP as of September 30, 2025 |
| US Workforce Reduction | 25% | Undertaken in November 2024 cost-saving restructuring |
| Cash and Cash Equivalents | $25.135M | As of September 30, 2025, down from $31.741 million at December 31, 2024 |
| Q2 2025 Net Loss | $1.05M | Increased from $1.00M in Q2 2024, indicating widening losses. |
| YTD 2025 Net Loss | $4.12M | Increased from $3.99M in YTD 2024, showing sustained unprofitability. |
| Net Loss Per Share | $0.001 | Consistent for both Q2 and YTD 2025 and 2024, despite widening net losses. |
Forward-Looking Statements
- {"claim":"Archon Capital Management LLC will likely maintain a significant stake in Apyx Medical Corp for the foreseeable future.","entity":"Archon Capital Management LLC","targetDate":"Q3 2024","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Apyx Medical Corp (APYX)?
Apyx Medical Corp has 38 recent SEC filings from Jan 2024 to May 2026, including 16 8-K, 9 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of APYX filings?
Across 38 filings, the sentiment breakdown is: 1 bearish, 35 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Apyx Medical Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Apyx Medical Corp (APYX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Apyx Medical Corp?
Key financial highlights from Apyx Medical Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for APYX?
The investment thesis for APYX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Apyx Medical Corp?
Key executives identified across Apyx Medical Corp's filings include Stavros G. Vizirgianakis, Amy E. Culbert, Esq..
What are the main risk factors for Apyx Medical Corp stock?
Of APYX's 24 assessed filings, 1 were flagged high-risk, 11 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Apyx Medical Corp?
Recent forward-looking statements from Apyx Medical Corp include guidance on {"claim":"Archon Capital Management LLC will likely maintain a significant stake in Apyx Medical Corp for the foreseeabl.